Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
379 studies found for:    Endometrial Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Completed Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
22 Completed
Has Results
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Conditions: Neoplasms;   Neoplasms by Site;   Urogenital Neoplasms;   Genital Neoplasms, Female;   Uterine Neoplasms;   Endometrial Neoplasms;   Cancer of Endometrium;   Endometrial Cancer;   Cancer of the Endometrium;   Endometrium Cancer;   Neoplasms, Endometrial
Intervention: Drug: pemetrexed
23 Active, not recruiting Diet and Physical Activity in Uterine Cancer Survivors
Condition: Endometrial Neoplasms
Intervention: Behavioral: Shape-Up following cancer treatment
24 Active, not recruiting Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Conditions: Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer
Interventions: Drug: Carboplatin;   Drug: Olaparib
25 Active, not recruiting Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Conditions: Ovarian Cancer;   Endometrial Cancer;   Uterine Cervical Cancer
Interventions: Drug: Filgrastim;   Drug: Paclitaxel;   Drug: Carboplatin
26 Recruiting Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Conditions: Ovary Cancer;   Cervix Cancer;   Endometrium Cancer;   Bladder Cancer;   Prostate Cancer (CRPC);   Esophagus Cancer;   Lung Cancer (NSCLC)
Intervention: Drug: Tisotumab vedotin (HuMax-TF-ADC)
27 Recruiting Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Condition: Stage III-IV or Recurrent Endometrial Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
28 Recruiting Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
Conditions: Breast Cancer;   Endometrial Cancer
Interventions: Other: HLA vaginal gel (HyaloGYN®),;   Behavioral: questionnaires
29 Completed Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
Conditions: Endometrial Adenocarcinoma;   Stage I Uterine Corpus Cancer;   Stage I Uterine Sarcoma;   Stage II Uterine Corpus Cancer;   Stage II Uterine Sarcoma
Interventions: Procedure: Laparoscopic Surgery;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery
30 Completed
Has Results
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: carboplatin;   Drug: docetaxel;   Radiation: radiation therapy
31 Recruiting Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole
Conditions: Solid Tumors;   Ovarian Cancer;   Endometrial Cancer
Interventions: Drug: ARQ 092 + carboplatin + paclitaxel;   Drug: ARQ 092 + paclitaxel;   Drug: ARQ 092 + anastrozole
32 Withdrawn A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
Condition: Endometrial Cancer
Intervention: Drug: BMN 673
33 Active, not recruiting Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
34 Active, not recruiting Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Conditions: Endometrial Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC1 Uterine Corpus Cancer;   Stage IIIC2 Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Megestrol Acetate;   Drug: Tamoxifen Citrate;   Drug: Temsirolimus
35 Completed Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage III Uterine Corpus Cancer;   Stage IV Uterine Corpus Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Radiation: Radiation Therapy
36 Completed TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Condition: Endometrial Cancer
Interventions: Behavioral: Telemedicine Weight Management plus Wi-Fi Scale (Arm A);   Behavioral: Text for Diet (Text4Diet) Group (Arm B);   Behavioral: Enhanced Usual Care Group (Arm C)
37 Recruiting Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer
Conditions: Estrogen Receptor Positive;   Postmenopausal;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Ribociclib
38 Unknown  Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
39 Recruiting Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: carboplatin and paclitaxel;   Other: observation
40 Completed Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years